Shih-Ming Chen

Dr. Shih-Ming Chen


Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2019 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
CCChi‐Hua Chen
Chi‐Hua Chen
CCChun‐Bing Chen
Chun‐Bing Chen
CCChee Jen Chang
Chee Jen Chang
YLYu Jr Lin
Yu Jr Lin
CWChuang‐Wei Wang
Chuang‐Wei Wang
WCWenHung Chung
WenHung Chung

18 October 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MLMing-Chia Lee
Ming-Chia Lee
CCChen-Yuan Chiang
Chen-Yuan Chiang
CLChih-Hsin Lee
Chih-Hsin Lee
Cheng-Maw HoCheng-Maw Ho
Cheng-Maw Ho
CCChia-Hao Chang
Chia-Hao Chang
SCShih-Ming Chen
Shih-Ming Chen
Human studies on the use of metformin as host-directed therapy (HDT) for tuberculosis (TB) are rare. We performed a nationwide cohort study to evaluate the effect of metformin on mitigating the risk of active TB among patients with diabetes mellitus (DM). Among newly diagnosed DM patients identified in the Taiwan National Health Insurance Research Database, metformin users, defined on the basis of >90 cumulative defined daily doses within 1 year, and propensity-score-matched metformin nonusers were selected. The primary outcome was incident TB, identified using diagnostic criteria validated by real patient data at a medical center. Independent predictors were investigated using Cox regression analysis. Similar analysis was performed in a subpopulation without a history of hypertensive nephropathy and renal replacement therapy. A total of 88,866 metformin users and 88,866 propensity-score-matched nonusers were selected. Validation results showed that the TB diagnostic criteria had a sensitivity of 99.13% and specificity of 99.90%. During follow-up, 707 metformin users and 807 nonusers developed active TB. Metformin use was independently associated with a lower risk of incident TB (hazard ratio [HR]: 0.84 [0.74–0.96]). TB risk was lower in high-dose metformin users than in low-dose users (HR: 0.83 [0.72–0.97]). The effect of metformin remained when analysis was restricted in the subpopulation without renal function impairment. Newly diagnosed diabetic patients without contraindication should receive metformin as an anti-diabetic medication, with potential additional benefit against TB.

1 March 2021 in Journal of Affective Disorders
Verified
Journal Article
Closed access
MLMing-Chia Lee
Ming-Chia Lee
TPTzu-Rong Peng
Tzu-Rong Peng
CLChih-Hsin Lee
Chih-Hsin Lee
Jann-Yuan WangJann-Yuan Wang
Jann-Yuan Wang
JLJen-Ai Lee
Jen-Ai Lee
JSJeng-Chuan Shiang
Jeng-Chuan Shiang

3 July 2015 in SpringerPlus
Verified
Journal Article
Open access
PDF file
CCChu-kuang Chou
Chu-kuang Chou
SCShih-Ming Chen
Shih-Ming Chen
YLYi-Chieh Li
Yi-Chieh Li
THTzu-Chuan Huang
Tzu-Chuan Huang
JLJen-Ai Lee
Jen-Ai Lee
Methylglyoxal (MG) can cause protein glycation, resulting in cell damage and dysfunction. Accumulation of MG and its downstream metabolite N ε-(carboxyethyl)lysine (CEL) has been identified in several variations of nephropathy, including diabetic, hypertensive, and gentamicin-induced nephropathies. In this study, we investigated the effects of low-molecular-weight chitosan (lmw-chitosan) on MG-induced carbonyl stress in aristolochic acid-induced nephropathy. We used a buffer to investigate whether MG could be scavenged by lmw-chitosan in vitro. In addition, we also used a mouse model of aristolochic acid-induced nephropathy, which exhibits 12-fold greater accumulation of MG in the kidneys than that found in control animals, to examine whether lmw-chitosan could decrease MG levels in vivo. Examination of the binding of lmw-chitosan with MG in vitro demonstrated that the concentration of lmw-chitosan necessary to achieve 50% inhibition was 4.60 µg mL−1. Treatment with lmw-chitosan (500 mg kg−1 day−1 orally) for 14 days significantly decreased renal MG accumulation from 212.86 ± 24.34 to 86.15 ± 33.79 µg g−1 protein (p < 0.05) and CEL levels from 4.60 ± 0.27 to 2.84 ± 0.28 µmol µg−1 protein (p < 0.05) in the aristolochic acid-induced nephropathy model. These data suggest that lmw-chitosan might represent a novel treatment modality for MG-related diseases such as nephropathy.


7 May 2024 in General Hospital Psychiatry
Verified
Journal Article
Closed access
TPTzu-Rong Peng
Tzu-Rong Peng
HLHung-Hong Lin
Hung-Hong Lin
MLMing-Chia Lee
Ming-Chia Lee
SCShih-Ming Chen
Shih-Ming Chen